Comparative Pharmacology
Head-to-head clinical analysis: LOXAPINE SUCCINATE versus SPARINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOXAPINE SUCCINATE versus SPARINE.
LOXAPINE SUCCINATE vs SPARINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loxapine is a dibenzoxazepine antipsychotic that exerts its effects primarily through antagonism of dopamine D2 and serotonin 5-HT2A receptors. It also has moderate affinity for histamine H1, alpha-1 adrenergic, and muscarinic acetylcholine receptors.
Phenothiazine antipsychotic; blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors; also blocks alpha-adrenergic receptors, and has anticholinergic and antihistaminergic effects.
Initial: 10 mg twice daily orally; increase to 25-50 mg twice daily over 7-10 days; maximum 250 mg/day. IM: 12.5-50 mg every 4-6 hours.
Promazine hydrochloride: 25-50 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 300 mg/day. Alternatively, oral: 25-200 mg every 4-6 hours; maximum 1000 mg/day. Route and frequency depend on indication and patient response.
None Documented
None Documented
Terminal elimination half-life: 12–19 hours (mean 16 hours) after oral administration; steady-state reached within 3–5 days.
Terminal elimination half-life: 10-20 hours; clinical context: allows once or twice daily dosing; extended in elderly and hepatic impairment
Renal (approximately 60% as metabolites, <1% unchanged) and fecal (approximately 40% as metabolites).
Primarily renal (70-80% as metabolites, less than 1% unchanged); biliary/fecal (15-30%)
Category C
Category C
Antipsychotic
Antipsychotic